Abstract
The root cause of sickle cell anemia has been known for 7 decades, yet no curative therapies have been available other than allogeneic bone marrow transplantation, for which applicability is limited. Two potentially curative therapies based on gene therapy and gene editing strategies have recently received US Food and Drug Administration approval. This review surveys the nature of these therapies and the opportunities and issues raised by the prospect of definitive genetically based therapies being available in clinical practice.
References
1.
Strasser
BJ
. Linus Pauling's "molecular diseases": between history and memory
. Am J Med Genet
. 2002
;115
(2
):83
-93
.2.
Ingram
VM
. Gene mutation in human haemoglobin: the chemical difference between normal and sickle cell haemoglobin
. Nature
. 1957
;180
(4581
):326
-327
.3.
Hebbel
RP
, Vercellotti
GM
. Pathobiology of sickle cell disease. In: Hoffman
R
, Benz
EJ
, Silberstein
L
, eds. Hematology: Principles and Practice
. 8th ed.. Elsevier
; 2023
:585
-598
.4.
Menapace
LA
, Thein
SL
. Clinical aspects of sickle cell disease. In: Hoffman
R
, Benz
EJ
, Silberstein
L
, eds. Hematology: Principles and Practice
. 8th ed.. Elsevier
; 2023
:599
-629
.5.
Kanter
J
, Walters
MC
, Krishnamurti
L
, et al. Biologic and clinical efficacy of LentiGLobin for sickle cell disease
. N Engl J Med
. 2022
;386
(7
):617
-628
.6.
Steinberg
MH
. Fetal-like hemoglobin in sickle cell anemia
. N Engl J Med
. 2022
;386
(7
):689
-691
.7.
Xu
J
, Peng
C
, Sankaran
VG
, et al. Correction of sickle cell disease in adult mice by interference with fetal hemoglobin silencing
. Science
. 2011
;334
(6058
):993
-996
.8.
Bauer
DE
, Kamran
SC
, Lessard
S
, et al. An erythroid enhancer of BCL11A subject to genetic variation determines fetal hemoglobin level
. Science
. 2013
;342
(6155
):253
-257
.9.
Frangoul
H
, Altshuler
D
, Cappellini
MD
, et al. CRISPR_Cas9 gene editing for sickle cell anemia and β-thalassemia
. N Engl J Med
. 2021
;384
(3
):252
-260
.10.
Stanton
D
. Bluebird wins US approval for world’s most expensive drug, Bioprocess International
. Accessed 10 August 2022. https://bioprocessintl.com/bioprocess-insider/therapeutic-class/bluebird-wins-us-approval-for-worlds-most-expensive-drug-zynteglo/007/5584_2018_331.PMID:30715679.11.
Goyal
S
, Tisdale
J
, Schmidt
M
, et al. Acute myeloid leukemia after gene therapy for sickle cell disease
. N Engl J Med
. 2022
;386
(2
):138
-147
.12.
Stonestrom
AJ
, Levine
RL
. The hematopoietic saga of clonality in sickle cell disease
. J Clin Invest
. 2022
;132
(5
):e158251
.13.
Li
C
, Georgakopoulou
A
, Newby
GA
, et al. In vivo HSC prime editing rescues sickle cell disease in a mouse model
. Blood
. 2023
;141
(17
):2085
-2099
.14.
Breda
L
, Papp
TE
, Triebwasser
MP
, et al. In vivo hematopoietic stem cell modification by mRNA recovery
. Science
. 2023
;381
(6656
):436
-443
.15.
Newby
GA
, Yen
JS
, Woodard
KJ
, et al. Base editing of haematopoietic stem cells rescues sickle cell disease in mice
. Nature
. 2021
;595
(7866
):295
-302
.16.
Esrick
EB
, Lehmann
LE
, Biffi
A
, et al. Post-transcriptional genetic silencing of BCL11A to treat sickle cell disease
. N Engl J Med
. 2021
;384
(3
):205
-215
.17.
Sharma
A
, Boelens
JJ
, Cancio
M
, et al. CRISPR-Cas9 editing of the HBG1 and HBG2 promoters to treat sickle cell disease
. N Engl J Med
. 2023
;389
(9
):820
-832
.© 2024 American Society of Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
2024
You do not currently have access to this content.
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal